Connor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 454,259 shares of the biotechnology company’s stock, valued at approximately $3,330,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.32% of Aurinia Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in AUPH. ProShare Advisors LLC raised its position in shares of Aurinia Pharmaceuticals by 9.1% in the first quarter. ProShare Advisors LLC now owns 34,464 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 2,873 shares during the period. Vanguard Group Inc. boosted its position in Aurinia Pharmaceuticals by 1.4% during the first quarter. Vanguard Group Inc. now owns 1,531,617 shares of the biotechnology company’s stock worth $7,673,000 after purchasing an additional 21,119 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Aurinia Pharmaceuticals by 15.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 38,952 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 5,079 shares during the period. Virtu Financial LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the first quarter valued at approximately $78,000. Finally, Cetera Advisors LLC raised its stake in shares of Aurinia Pharmaceuticals by 18.9% during the 1st quarter. Cetera Advisors LLC now owns 60,139 shares of the biotechnology company’s stock worth $301,000 after buying an additional 9,547 shares during the period. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $8.43, for a total transaction of $38,415.51. Following the transaction, the director now owns 13,356 shares in the company, valued at approximately $112,591.08. This trade represents a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 4.30% of the stock is currently owned by company insiders.

Aurinia Pharmaceuticals Price Performance

Aurinia Pharmaceuticals stock opened at $8.86 on Monday. The company has a fifty day simple moving average of $7.43 and a 200-day simple moving average of $6.35. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of -59.06 and a beta of 1.45. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.71 and a 52-week high of $9.74.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, September 6th. StockNews.com raised shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Aurinia Pharmaceuticals currently has an average rating of “Buy” and an average price target of $10.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.